Novo Nordisk CEO's testimony before US Senate panel set for Sept. 24

Washington: Novo Nordisk chief executive Lars Jorgensen's testimony before the U.S. Senate health committee on U.S. prices for weight loss drugs Ozempic and Wegovy will take place on Sept. 24, committee chairman Senator Bernie Sanders said on Monday.e

The Senate Committee on Health, Education, Labor, and Pensions had said earlier this month that Jorgensen agreed to testify voluntarily in a hearing but did not specify a date.

"The Committee looks forward to Mr. Jorgensen answering a very simple question: Why does he think it's acceptable to charge Americans up to 10 or 15 times more for Ozempic and Wegovy than people in Europe and other major countries?" Sanders said in a statement.

(Reporting by Ahmed Aboulenein)